FOCUS ON GCA REMISSION

and reducing steroids

RINVOQ is used to treat adults with giant cell arteritis (GCA).

The first and only once-daily non-steroid pill approved to treat GCA

In a clinical trial, RINVOQ has been proven to help MORE people with GCA achieve remission than those on steroids alone. Those in remission on RINVOQ were able to:

Taper off steroids

in 6 months

Rapidly reach remission

at 3 months

Stay in remission

even at 1 year

Remission is defined as an absence of signs or symptoms of GCA.

Most people on RINVOQ were steroid-free 2x faster. RAPID steroid taper on RINVOQ is 6 months. Steroid taper without RINVOQ is 1 year.
More people on RINVOQ + 6- month steroid taper stayed in remission from 3 months to 1 year. 46% of patients achieved lasting remission on RINVOQ 15mg (plus 6-month steroid taper) vs 29% on 1-year steroid taper without RINVOQ. RINVOQ = 209 Patients 1-yr steroid taper without RINVOQ = 112 patients

Select Important Safety Information

RINVOQ may cause serious side effects, including:

  • Serious Infections, Cancer and Immune System Problems, and Blood Clots.
  • Increased risk of death in people age 50+ with at least 1 heart disease risk factor.
  • Increased risk of major cardiovascular events, such as heart attack, stroke, or death in people age 50+ with at least 1 heart disease risk factor, especially in current or past smokers.
  • Serious allergic reactions. Do not take if allergic to RINVOQ or its ingredients.

Safety Considerations

RINVOQ may cause serious side effects, including:

  • Serious infections. RINVOQ can lower ability to fight infections. Serious infections, some fatal, occurred, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses.
  • Increased risk of death in people age 50+ with at least 1 heart disease risk factor.
  • Cancer and immune system problems. Increased risk of some cancers, including lymphoma and skin. Current or past smokers have higher risk for lymphoma and lung cancer.
  • Increased risk of major cardiovascular events such as heart attack, stroke, or death in people age 50+ with at least 1 heart disease risk factor, especially in current or past smokers.
  • Blood clots, some fatal, in veins of the legs or lungs and arteries. This occurred more often in people 50+ with at least 1 heart disease risk factor.
  • Serious allergic reactions. Do not take if allergic to RINVOQ or its ingredients.
  • Tears in the stomach or intestines; changes in certain laboratory test results.

Learn more about these and the full Important Safety Information below.

Stay informed

Have tips, tools, and news about RINVOQ delivered right to your inbox.

Learn how RINVOQ works to reduce GCA symptoms